{
  "ticker": "BIO",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02973643",
  "id": "02973643",
  "pages": 15,
  "price_sensitive": true,
  "date": "20250729",
  "time": "0842",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250729/pdf/06m7n0dj3935q3.pdf",
  "summary": "### **Material Information Summary (Quarterly Report - Appendix 4C)**  \n\n#### **Financial & Operational Highlights:**  \n- **EBITDA (excl. SBP):** **$78k** (Q4), **>$900k expected for FY25**  \n- **Record Sales Revenue:**  \n  - **June 2025:** **$2.1m** (+50% vs PCP)  \n  - **Q4 2025:** **$5.04m** (+33% vs PCP)  \n  - **FY25 Annual:** **$18.4m** (+41% vs PCP)  \n- **Cash Balance:** **$2.75m** (up $52k QoQ)  \n- **Net Operating Cash Outflow:** **-$485k** (Q4)  \n- **Gross Margin:** **61% maintained for FY25**  \n- **First Full-Year Net Profit Expected for FY25**  \n\n#### **Capital & Liquidity:**  \n- **NAB Facility:** **$5m** secured ($3.5m invoice finance + $1.5m trade finance; **$2.9m drawn**).  \n- **Inventory Build:** **$1.3m** safety stock funded by NAB facility; total inventory **$4.3m** ($11m wholesale value).  \n- **Funding Runway:** **10 quarters** based on total available liquidity ($4.84m).  \n\n#### **Key Investments & Updates:**  \n- Launched **Activated Therapeutics** range with national pharmacy partners.  \n- Expanded international distribution (Canada, Ireland, New Zealand).  \n- Held **Activated Probiotics Symposium** to drive brand education.  \n\n---  \n**Omitted:** Director payments, routine operational details, forward-looking disclaimers.",
  "usage": {
    "prompt_tokens": 5572,
    "completion_tokens": 373,
    "total_tokens": 5945,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-28T23:02:09.774744"
}